Direct oral anticoagulants (DOACs) include dabigatran etexilate, a direct thrombin inhibitor, and specific inhibitors of activated coagulation factor X (FXa; e.g. apixaban, betrixaban, edoxaban, rivaroxaban).
Read the latest publication digest "Anticoagulation reversal for intracranial haemorrhage in the era of the direct oral anticoagulants".
Direct oral anticoagulants are increasingly used in clinical practice and have addressed many of the issues related to vitamin K antagonists. However, the lack of reversal in life-threatening situations raises concerns regarding patient...
In patients taking oral anticoagulants (OACs), the annual rate of intracranial hemorrhage is 0.3% to 0.6%. Of these bleeds, 46% to 86% are intracerebral; 13% to 45% are subdural, and 1% to 8% are subarachnoidal.
Read the latest publication digest "Managing bleeds related to oral factor Xa inhibitors with andexanet alfa or replacement agents".
The objectives of this study were to estimate and compare the efficacy of NOAC antidotes on bleeding reversal and death.
Background: Over the last ten years, a new class of drugs, known as the direct-acting oral anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy.
The worldwide increase in the aging population and the associated increase in the prevalence of atrial fibrillation and venous thromboembolism as well as the widespread use of direct oral anticoagulants (DOAC) have resulted...
Oral anticoagulants (OA) are effective drugs for treating and preventing the formation of blood clots in patients with atrial fibrillation, mechanical heart valves and venous thromboembolism but their therapeutic effect is always counterbalanced...
Read the latest publication digest "A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus?".